EudraCT No.: 2015-005043-13 CONFIDENTIAL WHEN COMPLETE



RATE-AF Follow-Up CRF



IDENTIFYING DETAILS				
Patient initials: Tria	Number:			
Date of visit: DD / M M / Y Y Y				
TIMEPOINTS				
Please indicate below, which visit this CRF relates to:				
6 months	12 months			
QUALITY OF LIFE QUESTIONNAIRES				
SF-3	No Yes			
Has the patient completed the following?	0-5L No Yes			
AF-E	QT No Yes			
BLOOD TESTS				
Clinical samples (all bloods to be taken non-fasted)				
Test	Test	Not Applicable		
Test Sodium: mmol/L	Test Albumin: g/L			
Sodium: mmol/L	Albumin: g/L			
Sodium: mmol/L Potassium: mmol/L	Albumin: g/L Calcium: mmol/L			
Sodium:	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L			
Sodium:	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L eGFR mL/min/ 1.73m² Not Applicable	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L eGFR mL/min/ 1.73m² Not Applicable	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L eGFR mL/min/ 1.73m² Not Applicable	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L			
Sodium:	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L HCT: L/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L eGFR mL/min/ 1.73m ² Not Applicable INR: Not CONCOMITANT MEDICATIONS	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L HCT: L/L			
Sodium: mmol/L Potassium: mmol/L Urea: mmol/L Creatinine: micromol/L eGFR mL/min/ 1.73m ² Not Applicable INR: Not Applicable CONCOMITANT MEDICATIONS Please indicate whether the patient is on any of the follo	Albumin: g/L Calcium: mmol/L Phosphate: mmol/L Magnesium mmol/L Hb: g/L HCT: L/L			

EudraCT:2015-005043	3-13		CONFI	DENTIAL WHEN COMPLETE		
Trial Number:		Date of Visit:				
Antiplatelet medication: No Yes						
If known, please indic	cate which medication(s	s) the patient is on from the	list below (choose as ma	any as required):		
Aspirin	Dipyridamole Prasugrel Clopidogrel Ticagrelor					
Antihypertensive medication: No Yes						
If known, please indicate which medication(s) the patient is on from the list below (choose as many as required):						
ACEi	ARB Thiazide/loop CCBs Alpha			Alpha-blockers		
Aldosterone antagonists	Others Plea	se specify:				
Inhalers for airway	disease: No	Yes				
MEDICAL HISTORY	Y					
Please provide detail	Is about the patients r	ecent medical history:				
	Modified EHRA score:	1 2a	2b 3	4		
	Guidance on selecting mo	odified EHRA score:				
Atrial Fibrillation	1: None; AF does not c	ause any symptoms				
Atrial Fibrillation		tivity not affected; patient not trou				
		ily activity not affected; patient tro				
		activity affected by symptoms rela	ating to AF			
4: Disabling; normal daily activity discontinued						
	Has the patient been of	liagnosed with heart failure	? No Yes			
Please complete the following:						
NYHA Functional Classification: I II II III III IV						
Heart Failure Guidance on selecting NYHA Functional Classification:						
a.r. a.i.a.r	I No limitation of physic	ical activity. Ordinary physical act	tivity does not cause undue fati	gue, palpitation or dyspnoea.		
	Slight limitation of ph dyspnoea.	n of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation or				
	causes fatigue, palpitation or					
Unable to carry out any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activities undertaken, discomfort increases.						
Has the patient undergone any cardiovascular procedures since their last study visit? No Yes						
If yes, please retrieve a relevant summary of procedure and file in the investigator site file						

EudraCT:2015-005043-13 CONFIDENTIAL WHEN COMPLETE				N COMPLETE		
Trial Number: Date of Visit: DD/MM/M/M/M/M/M/M/M/M/M/M/M/M/M/M/M/M/M						
Pacemaker						
Has the patient had a pacer	naker fitted since their last trial visit	:?	No	Yes		
If yes, please complete the	following section:					
When was the pacemaker fi	tted?	Y				
Type of pacemaker: Singl	e chamber Dua	l chamber				
Is the pacemaker? Pacing	only CD		CRT-D		CRT-F	
Is the patient pacemaker de	pendant? No Yes					
Reason for implantation:	Atrial fik Bradycardia (e.g. with brady syr		h	Heart failure	Sy	ncope
Please provide details of a	ny oral medications that the pati	ent is curre	ently taking			
	Oral medication				t dose & fi	
Туре	Agent/ Brand	No	Yes	Dose	Units	Frequency
Digoxin						
β-blocker						
Diltiazem						
Verapamil						
Amiodarone						
Others (please specify)						
Others (please specify)						
FOLLOW-UP PROCEDURES AND ASSESSMENTS						
12-lead ECG:						
Heart rate Dpm QRS duration ms QT interval ms						
Office blood pressure and heart rate. To be taken whilst patient is at rest, in a seated position:						
Radial artery heart rate:						
Radial artery heart rate: bpm Apical heart rate: bpm Calculate heart rate from at least 30 second measurement						
Salvalate fical trate from at le	aut du deconia inicadul cilicili					

EudraCT:2015-005	5043-13		CC	NFIDENTIAL WHEN COMPLETE
Trial Number:		Date	of Visit:	
Physical examina	ation:			
Does the patient h	ave any signs of heart failure?		No Yes	
If yes, please indic	cate which ones below:			
Lung crepitations	consistent with heart failure		No Yes	
Peripheral oedema	a		No Yes	
Raised jugular vein pressure No Yes				
Abnormal heart so	ounds		No Yes	
Please specify:				
Anthropometric r	neasurements:			
Weight:	kg, to nearest kg		Waist circumference: taken above the hip bones in expir- nearest cm	ation, to cm
Please provide de	etails of the patients recent (within	1 the la	<u>ist 7 days</u>) physical activity:	
During the last 7 days, how much time did the patient spend sitting on a week day? ———————————————————————————————————				minutes per weekday
During the last 7 days, on how many days did the patient walk for at least 10 minutes at a time?				
What is the total amount of time the patient spent walking over the last 7 days?				minutes per week
During the last 7 days, on many days did the patient undertake moderate physical activities? days per week				days per week
How much time in total has the patient spent over the last 7 days doing moderate physical activities?				
During the last 7 days, on how many days did the patient undertake vigorous physical activities?				
How much time in total has the patient spent over the last 7 days doing vigorous physical activities?			minutes per week	
Guidance on complet	ing physical activity fields:			
Ask the patient to think about the time they spent sitting on week days during the last 7 days. Include time spent at work, at home, while doing course work, and during leisure time. This may include time spent sitting at a desk, visiting friends, reading or sitting or lying down to watch television.				
Walking	Ask the patient to think about the time they s from place to place, and any other walking to			
Ask the patient to think about the time they spent undertaking activities which take moderate physical effort over the last 7 days Moderate physical activities are those that made them breathe somewhat harder than normal and may have included carrying light loads, bicycling at a regular pace, or doubles tennis. Do not include walking. Again, ask that the patient thinks about only those physical activities that they did for at least 10 minutes at a time.				
Ask the patient to think about all the vigorous activities which take hard physical effort that they did in the last 7 days. Vigorous activities are those that made them breathe much harder than normal and may include heavy lifting, digging, aerobics, or fast bicycling. Ask that the patient thinks about only those physical activities that they did for at least 10 minutes at a time.				

Trial Number: Date of Visit: DD / M M / Y Y Y							
Six-minute walk test:							
Did the patient undergo the six-minute walk test? No Yes							
Total time spent undertaking the test:]:[_	mir	n/s Total dista	ance covered:	m, to	nearest m	
Was the test stopped prematurely? No		Yes					
		Breathl	essness				
		Fatigue					
If you placed aposity the reason the process	duro woo	Claudio	ation				
If yes, please specify the reason the proceed stopped (choose one option):	Jule was	Chest p	pain				
		Other	ain e.g. joint				
		(please	specify)				
Peak heart rate: bpm							
Mini mental state examination (please re CRF:	efer to RA	ATE-AF W	orksheet). R	ecord <u>only</u> the total te	est score on	this	
MMSE total test score: /30							
TREATMENT COMPLIANCE							
Has the patient been compliant with drugs Assessed by asking the participant how much of				All Some] None		
If some, how compliant has the patient been? > 75 % > 50 − 75 % > 25 − 50 % ≤ 25 %							
ADVERSE EVENTS							
Please record patient reported adverse events:							
Since the last visit, has the participant been unwell or experienced any side-effects or other adverse events?							
If 'yes', please complete below: If a previously recorded AE has resolved or changed since the last visit, please update the AE records. No Yes Yes records.							
Did the event include any of the following?							
	No	Yes			No	Yes	
Gastrointestinal upset			Dizziness				
Blurred vision			Headache				
Rash			Lethargy				
Peripheral oedema			Upper respira	atory tract symptoms			
Symptomatic bradycardia			Symptomatic	hypotonsion			

EudraCT:2015-005043-13

CONFIDENTIAL WHEN COMPLETE

Trial Number:	Date of Visit: D D / M M / Y Y Y		
Other (please specify)			
Has the patient stopped taking trial medication	because of adverse event(s)? No Yes		
If yes, has the medication been stopped?	Temporarily Permanently		
If medication has been stopped permanently , last dose of medication taken?	what date was the		
If medication has been stopped temporarily,	Date stopped:		
please provide dates:	Date restarted:		
If the patient has stopped taking medication for <u>any reason other than adverse events,</u> please provide details below, including the date medication was stopped:			
	Date stopped:		
Serious adverse events			
SAE : Any adverse event, reaction or unexpected adverse reaction, respectively that: Results in death; is life threatening; requires hospitalisation or prolongation of existing hospitalisation; results in persistent or significant disability or incapacity; consists of a congenital anomaly.			
Since the last visit, has the participant experienced any serious adverse events? No Yes			
If 'yes', please complete an SAE form			
	-		
Follow-Up CRF completed by: You must have signed the trial signature and deleg	gation log Name:(please print)		
Date: / / / / / / / /	Signature:		